Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12030896

    PIKfyve inhibitors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12030911

    Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12029755

    Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12029735

    Polymorphic compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12029577

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12031130

    Composition for modifying target gene

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Editas Medicine, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12031147

    Adeno-associated virus virions with variant capsids and methods of use thereof

    The Regents of the University of California · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12030935

    Anti-PDGF-B antibodies and pharmaceutical composition thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12030970

    Curable composition and stereolithographic resin composition comprising same

    KURARAY CO., LTD. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12030953

    Chimeric antigen receptors, compositions, and methods

    Regents of the University of Minnesota · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12031136

    Treatment for skeletal diseases caused by intracellular protein trafficking defects

    The Board of Regents of the University of Oklahoma · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12030925

    Methods of treating hemophilia A

    BIOVERATIV THERAPEUTICS INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12029759

    Compositions and methods for treating neurological disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12029816

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    The Board of Regents of the University of Texas System · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12030863

    Prodrugs of urolithins and uses thereof

    Amazentis SA · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12030908

    Antimicrobial compounds, compositions, and uses thereof

    Lakewood Amedex, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12030897

    Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof

    Medshine Discovery Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12030958

    Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides

    The Regents of the University of Colorado · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. WO 2024146923

    INHIBITEURS DE POLYMÉRISATION DE TUBULINE

    AB SCIENCE [FR] · Granted Thu Jul 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12036241

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12036225

    Use of ibezapolstat to promote microbiome health

    Acurx Pharmaceuticals, Inc. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12036234

    Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic tissues

    Northwestern University · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12036255

    Bacteriophage compositions and methods for treatment of bacterial infections

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12036319

    Polyvalent sting activating compositions and uses thereof

    The Board of Regents of the University of Texas System · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12037616

    Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

    CRISPR THERAPEUTICS AG · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12036256

    Adoptive cellular therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12036280

    High concentration protein formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12037401

    Anti-TrkB monoclonal antibodies and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12036278

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics (Nevada), Inc. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12036266

    Activatable cytokine polypeptides and methods of use thereof

    Werewolf Therapeutics, Inc. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12036314

    Compositions and methods for in situ-forming tissue constructs

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12036231

    Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling

    The Board of Regents of the University of Texas System · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12036288

    Methods of using humanized FCγR mice to assay Fc regions

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12037363

    Peptides for Covid-19 prevention and treatment

    SOTIRA COVID, LLC · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12037388

    Anti-IL-33 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12037390

    Leptin antibodies and method of reducing leptin

    The Board of Regents of the University of Texas System · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12037374

    Peptides, hydrogel compositions and methods of use thereof

    Regents of the University of Minnesota · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12036198

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    VISTAGEN THERAPUETICS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12036211

    Nicorandil derivatives

    UNICYCIVE THERAPEUTICS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12036194

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12037607

    Methods of preparing hematopoietic progenitor cells in vitro

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.